FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) From Merck Animal Health to Treat and Control Asian Longhorned Tick and Gulf Coast Tick for 12 Months in Dogs

Key Takeaways

• FDA expands Bravecto Quantum label to include two tick species.
• Single injection protects dogs 12 months against eight tick types.
• Extended-release formulation improves compliance and year‑round parasite control.
• Asian longhorned and Gulf Coast ticks rapidly expanding in U.S.
• Product remains veterinarian‑only, ensuring safe administration.

Summary

Merck Animal Health announced that the FDA has approved an expanded label for its once‑yearly injectable parasite control, Bravecto Quantum, adding treatment and control of Asian longhorned tick (Haemaphysalis longicornis) and Gulf Coast tick (Amblyomma maculatum) for 12 months. The product already provides 12‑month protection against several other tick species and kills adult fleas, administered as a single subcutaneous injection by a veterinarian. The label extension addresses the growing geographic spread of these two tick species and reinforces Bravecto’s position as the longest‑lasting flea and tick solution for dogs in the United States.

Pulse Analysis

The rise of tick‑borne illnesses has reshaped the veterinary parasite‑control market, prompting manufacturers to seek longer‑acting, broader‑spectrum solutions. Bravecto Quantum, a fluralaner‑based injectable, already set a benchmark by delivering 12‑month flea and multi‑tick protection from a single dose. Its pharmacokinetic profile maintains therapeutic drug levels throughout the year, reducing the need for monthly topicals or chews and addressing owner fatigue that often leads to gaps in coverage.

The FDA’s label expansion to include Asian longhorned and Gulf Coast ticks reflects both epidemiological trends and strategic positioning. These species have expanded northward and southward, respectively, exposing dogs in new regions to pathogens such as severe fever with thrombocytopenia syndrome and Rickettsia. By covering eight tick species, Bravecto Quantum offers veterinarians a comprehensive, one‑stop preventive tool, enhancing client compliance and differentiating Merck from competitors still reliant on shorter‑duration products. The veterinarian‑only administration model also ensures proper dosing and monitoring for the rare neurologic events associated with isoxazoline class drugs.

Looking ahead, the expanded indication could drive incremental sales growth as veterinarians adopt the injectable for broader geographic markets. Pet owners increasingly value convenience, and a single annual visit aligns with preventive‑care schedules, potentially boosting clinic revenue through ancillary services. However, safety communication remains critical; while adverse event rates are low, clear guidance for animals with seizure histories will be essential to maintain trust. Overall, the label update solidifies Bravecto Quantum’s role as a premium, science‑driven option in the evolving landscape of canine parasite management.